Fluoxetine Drug Interactions: Complete FDA-Sourced Safety Guide

Fluoxetine is one of the most widely prescribed antidepressants in the United States. As a selective serotonin reuptake inhibitor (SSRI), it helps treat depression, anxiety, obsessive-compulsive disorder, and other conditions by balancing serotonin levels in the brain. However, like all medications, fluoxetine can interact dangerously with certain other drugs.

This guide reviews the most serious fluoxetine interactions documented in FDA drug labeling, explains the mechanisms behind them, and provides actionable guidance for patients and caregivers. All data comes directly from FDA-labeled drug records in our comprehensive database of over 250,000 medications.

What Fluoxetine Is and Why Interactions Matter

Fluoxetine works by blocking the reuptake of serotonin in the brain, allowing more of this neurotransmitter to remain active in synapses. This mechanism is effective for mood and anxiety regulation but also makes fluoxetine sensitive to interactions with other serotonergic drugs, medications that inhibit or are metabolized by certain liver enzymes, and drugs that affect heart rhythm.

Fluoxetine has a long half-life of 1–3 days in the body, and its primary metabolite norfluoxetine can persist for 4–16 days. This prolonged presence in your system is important because it means interactions can occur even after you stop taking fluoxetine, and it can take weeks for the drug to fully leave your body.

Critical Contraindicated Interactions: Do Not Use Together

According to FDA drug labeling, the following drug combinations with fluoxetine are contraindicated—meaning they should never be used together under any circumstances.

Monoamine Oxidase Inhibitors (MAOIs)

The FDA label states that serious, sometimes fatal reactions have been reported when fluoxetine is used with MAO inhibitors. Common MAOIs include phenelzine sulfate, tranylcypromine sulfate, and isocarboxazid.

Why this happens: Both fluoxetine and MAOIs increase serotonin availability in the brain but through different mechanisms. When combined, serotonin levels can rise to dangerously high levels, triggering serotonin syndrome—a life-threatening condition marked by agitation, confusion, rapid heart rate, muscle rigidity, and high fever.

Important timing note: Because fluoxetine remains in your body for weeks, a minimum of 5 weeks must elapse after stopping fluoxetine before starting an MAOI. Conversely, at least 2 weeks should pass after stopping an MAOI before beginning fluoxetine. Do not attempt to bridge these medications without explicit physician approval.

Antipsychotics That Prolong QT Interval

The FDA explicitly warns against combining fluoxetine with thioridazine and pimozide. Both are antipsychotic medications.

Why this is dangerous: Fluoxetine inhibits the CYP450 2D6 enzyme, which metabolizes these antipsychotics. This enzyme inhibition causes thioridazine and pimozide levels to rise in the bloodstream. At elevated concentrations, both drugs prolong the QT interval on an electrocardiogram (ECG)—the electrical period between heartbeats. Severe QT prolongation can trigger Torsades de pointes, a chaotic, potentially fatal heart rhythm.

Major Interactions: Requires Careful Monitoring

In addition to contraindicated combinations, FDA labeling identifies several major interactions that require dose adjustments and close monitoring:

Tricyclic Antidepressants (TCAs)

Medications like nortriptyline, amitriptyline, and doxepin are older antidepressants that are still prescribed today. The FDA label warns that fluoxetine inhibits CYP450 2D6, the enzyme responsible for metabolizing TCAs.

What happens: When fluoxetine is combined with a TCA, the TCA can accumulate to higher levels, increasing the risk of toxicity including irregular heartbeat, dizziness, and worsening depression.

Clinical guidance: The FDA states that TCA levels should be monitored during coadministration with fluoxetine and especially if fluoxetine has been recently discontinued. Dose adjustments of the TCA may be necessary.

Benzodiazepines

Common benzodiazepines include diazepam (Valium) and alprazolam (Xanax). These central nervous system depressants are often prescribed for anxiety and sleep.

The interaction: Fluoxetine can increase the half-life of diazepam, meaning it stays in your body longer. With alprazolam, increased plasma concentrations may occur, leading to excessive drowsiness, impaired coordination, and reduced psychomotor performance.

What to watch for: Increased sedation, confusion, slowed reaction time, and dizziness. These effects increase the risk of falls, accidents, and overdose.

Moderate and Minor Interactions

The FDA label also documents several moderate and minor interaction categories:

• Other serotonergic drugs: SSRIs, SNRIs, tramadol, linezolid, and certain migraine medications (triptans) can increase serotonin when combined with fluoxetine. While less likely to cause severe serotonin syndrome than with MAOIs, monitoring is still advised.
• Anticonvulsants: Fluoxetine may elevate phenytoin and carbamazepine levels, potentially causing anticonvulsant toxicity. Serum level monitoring and dose adjustment may be needed.
• Antipsychotics: Fluoxetine can increase haloperidol and clozapine levels through CYP2D6 inhibition, raising the risk of extrapyramidal side effects and other toxicities.
• Drugs affecting blood clotting: NSAIDs, aspirin, and warfarin may have potentiated anticoagulant or antiplatelet effects when combined with fluoxetine, increasing bleeding risk.
• Protein-bound drugs: Fluoxetine is highly protein-bound and may displace other protein-bound drugs, changing their plasma concentrations.

Who Is Most at Risk?

Certain populations face higher risk from fluoxetine interactions:

• Patients on multiple medications: Those taking more than one CNS-active or serotonergic drug face compounded risk.
• Older adults: Age-related changes in metabolism make interactions more likely to cause serious side effects.
• People with liver or kidney disease: Reduced drug clearance increases concentrations and interaction severity.
• Those with cardiac history: Patients with arrhythmias or QT prolongation baseline are at higher risk from QT-prolonging drug combinations.

What You Should Do

Do not stop or start any medication without consulting your doctor or pharmacist. If you are currently taking fluoxetine and are considering a new medication, or if you are about to start fluoxetine:

• Always inform your healthcare provider of all medications, supplements, and herbal products you are taking.
• Ask your pharmacist to review your full medication list for interactions—they are trained to spot these problems.
• Never combine fluoxetine with MAOIs, thioridazine, or pimozide under any circumstance.
• If you need to switch from fluoxetine to an MAOI (or vice versa), allow the full washout period recommended by your doctor.
• Report any new or worsening symptoms—confusion, rapid heartbeat, muscle stiffness, excessive bleeding, or severe sedation—to your healthcare provider immediately.

Bottom Line

Fluoxetine is a safe and effective medication when used appropriately, but it does carry significant interaction risks with certain drug classes. The FDA explicitly forbids its use with MAOIs and specific antipsychotics, and recommends careful monitoring when combined with TCAs, benzodiazepines, and other serotonergic drugs. The long half-life of fluoxetine makes timing and washout periods critical for safe medication transitions.

Your best defense is awareness and communication. Always provide a complete medication list to your healthcare team, ask questions, and use a comprehensive drug interaction checker to verify your specific combinations.

Check all your medications instantly using checkdruginteractions.com—the most comprehensive drug interaction checker on the internet. Our database contains over 250,000 FDA-labeled drug records and lets you check up to 20 drugs at once with no account required. Get instant, evidence-based interaction severity ratings sourced directly from the U.S. FDA and National Library of Medicine.